Reply: The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer by Ward, S E
Letter to the Editor
Reply: The clinical and economic benefits of capecitabine and
tegafur with uracil in metastatic colorectal cancer
SE Ward*,1
1School of Health and Related Research, University of Sheffield, Regent Court, 30 Regent Street, Sheffield S1 4DA, UK
British Journal of Cancer (2007) 96, 1490. doi:10.1038/sj.bjc.6603739 www.bjcancer.com
Published online 17 April 2007
& 2007 Cancer Research UK
                
Sir,
First, the issue of BNF price changes. The prices of the drugs
used in the analysis were the current BNF prices at the time the
analysis was undertaken. The subsequent price reduction for
tegafur-uracil (Uftoral) in March 2006 will, of course, have reduced
the cost of this regimen relative to the costs of the other regimens,
assuming that the prices of the other drugs have remained
unchanged. However, it is not clear from the letter how the
reported 59% reduction in drug costs is derived from the 30%
reduction in the price of tegafur-uracil capsules shown in the table.
Decision makers will need to take into account the cost of the
drugs to them at this point in time. The exact cost of these
regimens to different institutions may well vary because of
negotiated procurement discounts and will, therefore, need to be
considered by each institution individually.
The estimated costs of adverse events were subject to significant
uncertainty and this was explicitly stated in the article. At the time
of the analysis, evidence available from the tegafur-uracil trials did
not provide adequate details to allow accurate estimation. The
column relating to tegafur-uracil in Table 5 should have been
omitted from the paper as these resource use estimates were not
ultimately used in the modelling. The hospitalisation data from the
table (taken from Ollendorf, 1999) included all nonadministration-
related hospitalisations and were considered to be an overestimate
of treatment-related adverse events. An alternative assumption was
therefore made. Based on evidence that the adverse event profile
for tegafur-uracil is equivalent or superior to Mayo in nearly all
categories, it was assumed that the resource use rates for
treatment-related adverse events would be similar to those
incurred with the Mayo regimen. Therefore, for the purposes of
our analysis, a conservative assumption was taken that the
treatment-related adverse event costs for tegafur-uracil were the
same as the treatment-related adverse event costs of the Mayo
treatment. The report by Ward et al (2003) acknowledged that this
may be an overestimate and the same holds true for the BJC paper.
Owing to the explicitly stated uncertainties, a sensitivity analysis
was presented to demonstrate the impact of removing adverse
event costs from the analysis.
The focus of our analysis was to compare oral drugs with
intravenous regimens, rather than to seek to differentiate between
the oral drugs. We did not highlight the price difference between
the oral drugs in the discussion section nor draw any specific
conclusions from it. Current NICE guidance recommends that
‘capecitabine or tegafur with uracil (and folinic acid), to be taken
by mouth, should be among the first options considered for a
person with metastatic colorectal cancer. The choice about which
medicine to take should be made jointly by the patient and his or
her doctor, and the patient should be informed about the options
and the differences between the medicines so that he or she can be
fully involved in the decision.’
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